+

US20060024396A1 - Method of treating diabetes and obesity using carbohydrate absorption inhibitors - Google Patents

Method of treating diabetes and obesity using carbohydrate absorption inhibitors Download PDF

Info

Publication number
US20060024396A1
US20060024396A1 US10/803,873 US80387304A US2006024396A1 US 20060024396 A1 US20060024396 A1 US 20060024396A1 US 80387304 A US80387304 A US 80387304A US 2006024396 A1 US2006024396 A1 US 2006024396A1
Authority
US
United States
Prior art keywords
evening primrose
primrose seed
seed
extract
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/803,873
Inventor
Yotaro Konishi
Michio Aitani
Hiroshi Yamaguchi
Tsutomu Arimura
Tadashi Okada
Hiromichi Murai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/803,873 priority Critical patent/US20060024396A1/en
Publication of US20060024396A1 publication Critical patent/US20060024396A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins

Definitions

  • This invention relates to carbohydrate absorption inhibitor and method for manufacturing the same effective against e.g. diabetes prevention, diet, and so forth.
  • Polysaccharide (starch, glycogen or the like) contained in food is hydrolyzed by ⁇ -amylase in saliva and pancreas and converted into oligosaccharide such as maltose, isomaltose or the like, then decomposed to glucose by disaccharide degrading enzyme such as ⁇ -glucosidase or the like in the small intestine and absorbed.
  • ⁇ -amylase and ⁇ -glucosidase perform an important role as a digestive enzyme for carbohydrate in the body. These enzyme activities affect the blood glucose level. Therefore, it is important to control these enzyme activities for the preventions and medical treatments of diabetes mellitus and obesity.
  • diabetes mellitus There are two different types of diabetes mellitus. One is insulin-dependent diabetes mellitus (Type I diabetes) and the other is non-insulin dependent diabetes mellitus (Type II diabetes), and the latter type accounts for more than 90% in the incidence of diabetes mellitus.
  • Type I diabetes insulin-dependent diabetes mellitus
  • Type II diabetes non-insulin dependent diabetes mellitus
  • Type II diabetes is caused by derangement of carbohydrate and fat metabolism arising from an insufficient insulin action (for instance, insulin-hyposensitivity in the organ, insulin-hyposecretion in pancreas or the like) due to overeating.
  • Non-insulin dependent diabetes mellitus should be basically controlled by diet therapy or exercise therapy rather than medication. However, such self-control does not always correct the aforementioned metabolic derangement, and medication is very much counted on.
  • Extract from gymnema leaf, guava leaf, banaba leaf, mulberry leaf or the like is widely known as a plant-derived extract which is effective to correct the derangement of carbohydrate metabolism. From the viewpoint of safety, these plant-derived extracts are easily applied to food, drugs and medicines, or the like, therefore effective components or the like of the said plant-derived extracts are now being extensively researched.
  • This invention aims at providing inhibitor of carbohydrate absorption derived from evening primrose seed and method for manufacturing the said inhibitor of carbohydrate absorption which are significantly effective to prevent or relieve symptoms of diabetes mellitus and to prevent obesity.
  • Carbohydrate absorption inhibitor which is the subject matter in this invention is characterized by comprising an effective component of solvent extract of compressed cake derived from the defatted evening primrose, and wherein the said effective component contains polyphenol such as ellagic acid, gallic acid, pentagalloylglucose.
  • Carbohydrate absorption inhibitor in this invention is characterized in that defatting process is proceeded by using fat-soluble organic solvent.
  • Chemicals in this invention are characterized in that the aforementioned carbohydrate absorption inhibitor is contained.
  • Food and drink in this invention are characterized in that the aforementioned carbohydrate absorption inhibitor is contained.
  • the existing plant-derived extracts (guava, banaba and mulberry) have a strong inhibitory action against amylase, however the enzyme inhibitory activity against amylase is not sufficient.
  • extract (polyphenol) derived from evening primrose as disclosed in this invention indicates strong enzyme inhibition activities against amylase and glucosidase.
  • ethanol extract derived from the defatted evening primrose seed comprises a strong inhibitory action and consistent safety. Therefore it is appropriate to mix it with medicine to prevent diabetes mellitus or to diet
  • primrose is an annual grass, biennial grass or herbaceous perennial of oenothera genus. In rare cases, stem of evening primrose may be lignified and grow on bush. The followings are four representative examples.
  • species of evening primrose are not limited. Any species can be used.
  • Oil obtained from evening primrose seed is widely known.
  • the evening primrose oil contains a large amount of ⁇ -linolenic acid and is said to be effective against obesity, diabetes mellitus, hypercholesterolemia, alcohol dependence, aging, and disease caused by insufficient vitamin B 6 .
  • evening primrose oil is effective to inhibit the action in which linolic acid is converted into ⁇ -linolenic acid when virus infection is experienced, as well as to provide a medical treatment for asthma and atopic disease.
  • Some part of the compressed cake exhausted in the manufacturing process of evening primrose seed is used as an animal feeding staff, or is disposed of as an industrial waste.
  • a new usage of other components than the fat-soluble component of the evening primrose seed can be provided, and at the same time the effective component can be extracted from the compressed cake after taking out the evening primrose oil. It is significant to extract the high value-added effective component from the compressed cake and efficiently recycle the natural resources.
  • alcohol is used as an extracting solvent for the aforementioned evening primrose seed.
  • Ethanol is especially recommended. If ehanol is used, effective component (polyphenol) is efficiently extracted and can be used both for external application and food. According to other usages available, methanol, butanol or the like can be used.
  • the concentration of ethanol as an extracting solvent is preferably 70 to 85% (v/v). If the concentration of ethanol is less than 70% (v/V), polyphenol is not sufficiently extracted. And if the concentration exceeds 85% (v/v), seed oil easily dissolves into the extracting solvent.
  • alcohol extraction should be repeated preferably at different levels of concentration since the content ratio of polyphenol is improved.
  • the defatted evening primrose seed for alcohol extraction since polyphenol is concentrated in the defatted matter by removing oil from the seed.
  • hexane as a fat-soluble organic solvent for defatting since the extracted oil can be used for edible oil and also extract of defatted evening primrose seed can be used for foodstuff or the like. If the extract is used for other objectives than food, other non-polar solvent than hexane can be also used.
  • the aforementioned polyphenol derived from the evening primrose seed can be extracted preferably by solvent such as ethanol, aqueous ethanol, water or the like.
  • the extract contains gallic acid, ellagic acid, catechin, pentagalloylglucose.
  • Medicine described in this invention is suitable for the prevention of diabetes mellitus, i.e. the prevention or treatment of non-insulin dependent diabetes mellitus (Type II diabetes), or can be also used for the effective component of antiobesity drugs.
  • medicine in this invention can be orally administered in any shape of soft and/or hard capsule, tablet, granule, fine granule, or powder medicine.
  • the medicine in this invention can be administered by injection into body tissue, dermis, subdermal muscle or vein,
  • Concentration of polyphenol component can be varied according to various types of medicine. However, when the medicine is used by oral administration or mucomembranous absorption, the given dose should be 0.01 to 15.0 wt %. When the medicine is used by non-oral administration, the given dose should be 0.01 to 10 wt.
  • the dose mentioned above is only an example and can be varied according to various situations.
  • This invention suggests various embodiments of ordinary food and drink including snack food (such as chewing gums, candies, caramel candies (taffies), chocolates, cookies, jellies, gummy candies, other tablet shaped candies, or the like), noodles (such as Japanese buckwheat noodles called “Soba”, Japanese wheat noodles called “Udon”, Chinese noodle or the like), dairy products (such as milk, ice cream, yogurt or the like), seasoning (such as fermented soybean paste called “Miso”, soy sauce, or the like), soups and drinks (such as juice, soft drinks including carbonated drinks, coffee, black tea, green tea, isotonic drinks, or the like), of healthy food (such as food in supplement in tablet, capsule or the like), nutraceutical supplement (such as nutrition supplement drinks or the like).
  • snack food such as chewing gums, candies, caramel candies (taffies), chocolates, cookies, jellies, gummy candies, other tablet shaped candies, or the like
  • noodles such as Japanese buckw
  • Extract polyphenol derived from evening primrose seed is accordingly applied to those above or convenience food.
  • ethanol extract of evening primrose seed mixed with powdered cellulose can be spray dried or freeze-dried and converted into powder, granule, tablet, solution or the like, and then applied to various food and drink.
  • FIG. 1 on the attached sheet is a graph indicating a variation of blood glucose level of a normal rat after extracts of evening primrose seed and starch have been administered to the said rat.
  • FIG. 2 on the attached sheet is a graph indicating a variation of blood glucose level of a normal rat after extracts of evening primrose and sucrose have been administered to the said rat.
  • FIG. 3 on the attached sheet is an HPLC chart of the extract in this invention
  • FIG. 4 on the attached sheet is a graph indicating a suppressive effect on the elevation of blood glucose level of the nondiabetic subject.
  • FIG. 5 on the attached sheet is a graph indicating a suppressive effect on the elevation of blood glucose level of the mild diabetic subjects.
  • Embodiments of this invention are as follows.
  • Material Compressed cake obtained in the manufacturing process of evening primrose oil is used.
  • the compressed cake was crushed, refluxed by hexane, and then the defatted substance was obtained by removing the remaining oil from the said compressed cake.
  • the said defatted substance was fluxed in 70% (v/v) aqueous ethanol, and then the said ethanol extract was evaporated until carbohydrate absorption inhibitor (Embodiment 1) was obtained.
  • Inhibitory activity (5) of ⁇ -amylase in regard to the Embodiment 1 was determined by using an amylase activity measuring kit (“Amylase Test Wako” manufactured by Wako Pure Chemical Industries, Ltd., Japan), which is commercially available. Measuring method using human saliva-derived ⁇ -amylase is as follows.
  • substrate buffer solution 1.0 mL was added to the said mixture and incubated at 37° C. for 60 min. Then the said mixture was incubated in the boiling water for 5 min., and after the reaction stopped, coloring reagent (1.0 mL) was added and then the absorbance (660 nm) was measured.
  • IC 50 50% inhibition concentration against the ⁇ -amylase (derived from human saliva) was found to be 0.5 mg/mL.
  • IC 50 50% inhibition concentration against the ⁇ -amylase derived from pancreas of pig was identified by the same method.
  • the following chart shows the excellent inhibitory activities.
  • ⁇ -glucosidase inhibitory activity (%) in regard to the embodiment 1 (evening primrose seed extract) was identified by the following method.
  • 0.1 mol maleic acid buffer solution pH6.0
  • acetone powder in the intestinal canal of rat SIGMA CHEMICAL CO.
  • homogenized in ice by using a glass homogenizer, and then centrifugalized supernatant was diluted 20 times. Measuring method is shown below.
  • Sample solution (0.01 ml) was added to the enzyme solution (0.05 ml), then 0.1 M maleic buffer solution (0.64 ml), moreover, 33 mM 4-methylumbelliferyl- ⁇ -D-glucoside (0.3 ml) was added and then incubated at 37° C. for 30 min.
  • inhibitory activity against ⁇ -glucosidase of embodiment 1 is less effective than that of guava leaf extract (Comparison 1), banaba leaf extract (Comparison 2) and mulberry leaf extract (Comparison 3), it still has excellent inhibitory activity against ⁇ -glucosidase.
  • IC 50 50% inhibitory concentration against ⁇ -glucosidase was identified.
  • the embodiment 1 (evening primrose seed extract) comprises the inhibitory activity against both ⁇ -amylase and ⁇ -glucosidase, and effectively inhibits the degradation of carbohydrate.
  • Embodiment 1 After breeding 5-week old male wister rats (Clear Japan, Inc.) for more than one week, then 6 to 8-week old wister rats were used during the test. Without giving any food to the rats for 24 hours, sample of Embodiment 1 (at the rate of 0.5 g per kg of weight) was dissolved in distilled water, and carbohydrate (starch and sucrose: at the rate of 2 g per kg of weight) was dissolved in distilled water, then both were administered to the stomach sound.
  • the blood glucose level rapidly increased before 30 min passed, on the contrary, the blood glucose level of the rats of which the embodiment 1 (evening primrose seed extract) was administered slowly increased.
  • “Evening primrose seed extract” shown below is powdered and dried ethanol extract of evening primrose seed obtained under the same conditions of the aforementioned embodiment 1.
  • Composition 1 Chewing gums Sugar 53.0 wt % Gum base 20.0 Glucose 10.0 Starch syrup 16.0 Flavoring agent 0.5 Evening primrose seed extract 0.5 100.0 wt % Composition 2: Gummy candies Reduced syrup 40.0 wt % Granulated sugar 20.0 Glucose 20.0 Gelatin 4.7 Water 9.68 Japanese apricot (Ume) juice 4.0 Japanese apricot (Ume) flavor 0.6 Coloring agent 0.02 Evening nrimrose seed extract 1.0 100.0 wt % Composition 3: Candies Sugar 50.0 wt % Starch syrup 33.0 Water 14.4 Organic acid 2.0 Flavoring agent 0.2 Evening primrose seed extract 0.4 100.0 wt % Composition 4: Soft capsule Rice germ oil 8
  • the structure of the extract obtained from the embodiment 1 and similar method contained ellagic acid, gallic acid, catechin, and pentagalloylglucose.
  • HPLC chart is shown in FIG. 3 .
  • the rise in blood glucose level of the patient suffering from the mild diabetes mellitus with the fasting blood glucose level of 110 mg/dl to 180 mg/dl is more significantly controlled than the rise in postprandial blood glucose level of the patient in a placebo group.
  • CHART 4 Change in the value of insulin when conducting the food loading test ( ⁇ U/dl) Before loading test 30 min 60 min 90 min 120 min Control 13.3 ⁇ 15.0 28.4 ⁇ 23.9 40.0 ⁇ 31.1 43.6 ⁇ 28.1 50.1 ⁇ 30.0 group Evening primrose 12.7 ⁇ 9.8 22.4 ⁇ 14.5 35.8 ⁇ 33.1 43.7 ⁇ 35.9 43.7 ⁇ 31.4 extract group Significant n.s n.s n.s n.s n.s n.s difference between groups
  • evening primrose comprises an effective function to control the rapid rise in blood glucose-level after food loading. Since the rapid rise in blood glucose level is controlled, the rapid increase in insulin secretion becomes moderate. This indicates that evening primrose extract is effective to reduce the burden of insulin secretion of the patient suffering from insulin deficiency diabetes mellitus.
  • the amount of carbohydrate taken into the human body can be controlled by inhibiting the digestion of starch and saccharides, i.e., by inhibiting the activity of a amylase and ⁇ -glucosidase which are saccharides degrading enzyme inherent in living body.
  • the risk of type II diabetes mellitus can be especially controlled by a mechanism which keeps the postprandial blood glucose level low.
  • the said mechanism is significantly safer and harmless than the direct prevention to control the insulin secretion, and from the viewpoint of the preventive medicine in the latest mainstream of alternative medicine, it is considered to be inventive that the said mechanism can be applied to the function of the evening primrose leaf extract.
  • this invention can provide the significant effectiveness to prevent and treat diabetes mellitus and obesity since the rise in blood glucose level by absorption of saccharides becomes moderate.
  • effective component is extracted from evening primrose seed which is known as an ingredient of edible oil, therefore the said component is safe and has no side effect or the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

This invention provides carbohydrate absorption inhibitor derived from evening primrose seed which is significantly effective to prevent and cure diabetes mellitus and prevent obesity, and the manufacturing method of the same. Carbohydrate absorption inhibitor in this invention is characterized that the effective component is an alcohol extract of evening primrose seed. The aforementioned evening primrose seed is preferably a defatted evening primrose seed. Extracting solvent of the aforementioned evening primrose seed is preferably ethanol, or preferably a 70 to 85% (v/v) aqueous ethanol. Also, this invention is characterized that the carbohydrate absorption inhibitor is an effective component of polyphenol derived from evening primrose seed. The polyphenol is preferably one or more substances selected from among gallic acid, ellagic acid, catechin, pentagalloylglucose, procyanidin, and proantocyanidin. The manufacturing method of the carbohydrate absorption inhibitor in this invention is characterized to be composed of the following processes A to C. Process A: evening primrose is compressed, oil is separated then the compressed cake is obtained. Process B: The aforementioned compressed cake is defatted in fat-soluble organic solvent, and defatted substance is obtained. Process C: The aforementioned defatted substance is extracted by alcohol, and then this extracted liquid is concentrated or evaporated.

Description

    FIELD OF THE INVENTION
  • This invention relates to carbohydrate absorption inhibitor and method for manufacturing the same effective against e.g. diabetes prevention, diet, and so forth.
    • BACKGROUND OF THE INVENTION
  • Polysaccharide (starch, glycogen or the like) contained in food is hydrolyzed by α-amylase in saliva and pancreas and converted into oligosaccharide such as maltose, isomaltose or the like, then decomposed to glucose by disaccharide degrading enzyme such as α-glucosidase or the like in the small intestine and absorbed.
  • Thus, α-amylase and α-glucosidase perform an important role as a digestive enzyme for carbohydrate in the body. These enzyme activities affect the blood glucose level. Therefore, it is important to control these enzyme activities for the preventions and medical treatments of diabetes mellitus and obesity.
  • There are two different types of diabetes mellitus. One is insulin-dependent diabetes mellitus (Type I diabetes) and the other is non-insulin dependent diabetes mellitus (Type II diabetes), and the latter type accounts for more than 90% in the incidence of diabetes mellitus.
  • The latter type (Type II diabetes) is caused by derangement of carbohydrate and fat metabolism arising from an insufficient insulin action (for instance, insulin-hyposensitivity in the organ, insulin-hyposecretion in pancreas or the like) due to overeating.
  • Non-insulin dependent diabetes mellitus (Type II diabetes) should be basically controlled by diet therapy or exercise therapy rather than medication. However, such self-control does not always correct the aforementioned metabolic derangement, and medication is very much counted on.
  • However, it is necessary to consider side effects, dosage and usage of the medicine. In general, medicine is usually an intermixture of various components. Therefore, it is necessary to consider the side effect each component has and adverse effect caused by a prolonged dosage of each component.
  • Extract from gymnema leaf, guava leaf, banaba leaf, mulberry leaf or the like is widely known as a plant-derived extract which is effective to correct the derangement of carbohydrate metabolism. From the viewpoint of safety, these plant-derived extracts are easily applied to food, drugs and medicines, or the like, therefore effective components or the like of the said plant-derived extracts are now being extensively researched.
  • Against this background, the inventors in this invention have been investigating contents of polyphenol, SOD-like activities or the like in regard to the various plant-derived extracts, then finally came to focus on ethanol extract of evening primrose seed.
  • After each of the aforementioned experiments has been conducted, they came to know the fact that this extract contains various polyphenol effective to inhibit the carbohydrate absorption.
  • This invention aims at providing inhibitor of carbohydrate absorption derived from evening primrose seed and method for manufacturing the said inhibitor of carbohydrate absorption which are significantly effective to prevent or relieve symptoms of diabetes mellitus and to prevent obesity.
    • SUMMARY OF THE INVENTION
  • Carbohydrate absorption inhibitor which is the subject matter in this invention is characterized by comprising an effective component of solvent extract of compressed cake derived from the defatted evening primrose, and wherein the said effective component contains polyphenol such as ellagic acid, gallic acid, pentagalloylglucose.
  • Carbohydrate absorption inhibitor in this invention is characterized in that extracting solvent of the compressed cake derived from the aforementioned evening primrose seed is aqueous ethanol (water/ethanol=15 to 30/70 to 85% (v/v)).
  • Carbohydrate absorption inhibitor in this invention is characterized in that defatting process is proceeded by using fat-soluble organic solvent.
  • Chemicals in this invention are characterized in that the aforementioned carbohydrate absorption inhibitor is contained.
  • Food and drink in this invention are characterized in that the aforementioned carbohydrate absorption inhibitor is contained.
  • According to the experiment conducted by the inventors, the existing plant-derived extracts (guava, banaba and mulberry) have a strong inhibitory action against amylase, however the enzyme inhibitory activity against amylase is not sufficient.
  • On the contrary, extract (polyphenol) derived from evening primrose as disclosed in this invention indicates strong enzyme inhibition activities against amylase and glucosidase. Especially the ethanol extract derived from the defatted evening primrose seed comprises a strong inhibitory action and consistent safety. Therefore it is appropriate to mix it with medicine to prevent diabetes mellitus or to diet
  • Evening primrose is an annual grass, biennial grass or herbaceous perennial of oenothera genus. In rare cases, stem of evening primrose may be lignified and grow on bush. The followings are four representative examples.
      • {circle around (1)} Oenothera laciniata
      • {circle around (2)} Oenothera striata
      • {circle around (3)} Oenothera biennis
      • {circle around (4)} Oenothera erythrosepala
  • In this invention, species of evening primrose are not limited. Any species can be used.
  • Oil obtained from evening primrose seed is widely known. The evening primrose oil contains a large amount of γ-linolenic acid and is said to be effective against obesity, diabetes mellitus, hypercholesterolemia, alcohol dependence, aging, and disease caused by insufficient vitamin B6.
  • Also it is widely known that evening primrose oil is effective to inhibit the action in which linolic acid is converted into γ-linolenic acid when virus infection is experienced, as well as to provide a medical treatment for asthma and atopic disease.
  • In regard to the fat-soluble component of evening primrose seed, physiological activity is now being researched, however, there is no report about the physiological activity of other substance than fat-soluble component.
  • Some part of the compressed cake exhausted in the manufacturing process of evening primrose seed is used as an animal feeding staff, or is disposed of as an industrial waste.
  • In this invention, a new usage of other components than the fat-soluble component of the evening primrose seed can be provided, and at the same time the effective component can be extracted from the compressed cake after taking out the evening primrose oil. It is significant to extract the high value-added effective component from the compressed cake and efficiently recycle the natural resources.
  • To efficiently extract the effective component (polyphenol) for the carbohydrate absorption inhibition, alcohol is used as an extracting solvent for the aforementioned evening primrose seed. Ethanol is especially recommended. If ehanol is used, effective component (polyphenol) is efficiently extracted and can be used both for external application and food. According to other usages available, methanol, butanol or the like can be used.
  • The concentration of ethanol as an extracting solvent is preferably 70 to 85% (v/v). If the concentration of ethanol is less than 70% (v/V), polyphenol is not sufficiently extracted. And if the concentration exceeds 85% (v/v), seed oil easily dissolves into the extracting solvent.
  • Also, alcohol extraction should be repeated preferably at different levels of concentration since the content ratio of polyphenol is improved.
  • Furthermore, it is preferable to use the defatted evening primrose seed for alcohol extraction since polyphenol is concentrated in the defatted matter by removing oil from the seed. For instance, it is preferable to separate the oil from the evening primrose seed by compressing the said seed, and then to extract and separate the remaining oil of the compressed matter by fat-soluble organic solvent.
  • It is preferable to use hexane as a fat-soluble organic solvent for defatting since the extracted oil can be used for edible oil and also extract of defatted evening primrose seed can be used for foodstuff or the like. If the extract is used for other objectives than food, other non-polar solvent than hexane can be also used.
  • The aforementioned polyphenol derived from the evening primrose seed can be extracted preferably by solvent such as ethanol, aqueous ethanol, water or the like. According to the research by inventors, the extract contains gallic acid, ellagic acid, catechin, pentagalloylglucose.
  • Medicine described in this invention is suitable for the prevention of diabetes mellitus, i.e. the prevention or treatment of non-insulin dependent diabetes mellitus (Type II diabetes), or can be also used for the effective component of antiobesity drugs. For instance, medicine in this invention can be orally administered in any shape of soft and/or hard capsule, tablet, granule, fine granule, or powder medicine. On the other hand, the medicine in this invention can be administered by injection into body tissue, dermis, subdermal muscle or vein,
  • Given dose varies depending on the mode of administration, condition of the disease, age of the patient, or the like. Adults can take the effective component of 0.5 to 5,000 mg per day and children can take 0.5 to 3,000 mg per day.
  • Concentration of polyphenol component can be varied according to various types of medicine. However, when the medicine is used by oral administration or mucomembranous absorption, the given dose should be 0.01 to 15.0 wt %. When the medicine is used by non-oral administration, the given dose should be 0.01 to 10 wt. The dose mentioned above is only an example and can be varied according to various situations.
  • This invention suggests various embodiments of ordinary food and drink including snack food (such as chewing gums, candies, caramel candies (taffies), chocolates, cookies, jellies, gummy candies, other tablet shaped candies, or the like), noodles (such as Japanese buckwheat noodles called “Soba”, Japanese wheat noodles called “Udon”, Chinese noodle or the like), dairy products (such as milk, ice cream, yogurt or the like), seasoning (such as fermented soybean paste called “Miso”, soy sauce, or the like), soups and drinks (such as juice, soft drinks including carbonated drinks, coffee, black tea, green tea, isotonic drinks, or the like), of healthy food (such as food in supplement in tablet, capsule or the like), nutraceutical supplement (such as nutrition supplement drinks or the like). Extract (polyphenol) derived from evening primrose seed is accordingly applied to those above or convenience food. For example, ethanol extract of evening primrose seed mixed with powdered cellulose can be spray dried or freeze-dried and converted into powder, granule, tablet, solution or the like, and then applied to various food and drink.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 on the attached sheet is a graph indicating a variation of blood glucose level of a normal rat after extracts of evening primrose seed and starch have been administered to the said rat.
  • FIG. 2 on the attached sheet is a graph indicating a variation of blood glucose level of a normal rat after extracts of evening primrose and sucrose have been administered to the said rat.
  • (Additional Part)
  • FIG. 3 on the attached sheet is an HPLC chart of the extract in this invention
  • FIG. 4 on the attached sheet is a graph indicating a suppressive effect on the elevation of blood glucose level of the nondiabetic subject.
  • FIG. 5 on the attached sheet is a graph indicating a suppressive effect on the elevation of blood glucose level of the mild diabetic subjects.
  • (End of the Additional Part)
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Embodiments of this invention are as follows.
  • (Manufacture of the Carbohydrate Absorption Inhibitor)
  • Material: Compressed cake obtained in the manufacturing process of evening primrose oil is used.
  • Firstly, the compressed cake was crushed, refluxed by hexane, and then the defatted substance was obtained by removing the remaining oil from the said compressed cake. Secondly, the said defatted substance was fluxed in 70% (v/v) aqueous ethanol, and then the said ethanol extract was evaporated until carbohydrate absorption inhibitor (Embodiment 1) was obtained.
  • (Inhibitory Activity Against α-Amylase)
  • Inhibitory activity (5) of α-amylase in regard to the Embodiment 1 (extract of evening primrose seed) was determined by using an amylase activity measuring kit (“Amylase Test Wako” manufactured by Wako Pure Chemical Industries, Ltd., Japan), which is commercially available. Measuring method using human saliva-derived α-amylase is as follows.
  • After incubating a mixture of the human saliva-derived α-amylase solution (0.02 mL) and sample solution (0.01 mL) at 37° C. for 5 min., substrate buffer solution (1.0 mL) was added to the said mixture and incubated at 37° C. for 60 min. Then the said mixture was incubated in the boiling water for 5 min., and after the reaction stopped, coloring reagent (1.0 mL) was added and then the absorbance (660 nm) was measured.
  • After calculating the enzyme activity (%) based on this measured value, the inhibitory activity (5) was calculated by the following formula. The enzyme activity was calculated based on the absorbance (100%) measured under condition where no sample coexisted.
    Inhibitory activity (%)=100−enzyme activity (%)
  • Inhibitory activities (%) in regard to other plant-derived extracts of guava leaf (Comparison 1), banaba leaf (Comparison 2) and mulberry leaf (Comparison 3) were also calculated by the same method as shown in the following chart 1.
    CHART 1
    Concentration Inhibitory
    Classification Exract (mg/ml) activity (%)
    Embodiment 1 Evening 1.0 100
    primrose seed
    Comparison 1 Guava leaf 1.0 0
    Comparison 2 Banaba leaf 1.0 80
    Comparison 3 Mulberry leaf 1.0 0
  • As described in the above chart 1, it is clear that α-amylase inhibitory activity against the embodiment 1 is higher than any of the others.
  • Also, after measuring the enzyme activity to the variation of concentration regarding the embodiment 1 (evening primrose seed extract) by using the same method, IC50 (50% inhibition concentration) against the α-amylase (derived from human saliva) was found to be 0.5 mg/mL.
  • In connection with the embodiment 1 (evening primrose seed extract), gallic acid, ellagic acid, catechin, and pentagalloylglucose, IC50 (50% inhibition concentration) against the α-amylase derived from pancreas of pig was identified by the same method. The following chart shows the excellent inhibitory activities.
    Chemical compound IC50 (mg/ml)
    Embodiment 1 (evening primrose seed extract) 0.01
    Gallic acid 0.4
    Ellagic acid >1.0
    Catechin 0.8
    Pentagalloylglucose 0.02
    [α-glucosidase inhibitory activity]
  • Next, α-glucosidase inhibitory activity (%) in regard to the embodiment 1 (evening primrose seed extract) was identified by the following method. As for the α-glucosidase for this measurement, 0.1 mol maleic acid buffer solution (pH6.0) was added to the acetone powder in the intestinal canal of rat (SIGMA CHEMICAL CO.) and homogenized in ice by using a glass homogenizer, and then centrifugalized supernatant was diluted 20 times. Measuring method is shown below.
  • Sample solution (0.01 ml) was added to the enzyme solution (0.05 ml), then 0.1 M maleic buffer solution (0.64 ml), moreover, 33 mM 4-methylumbelliferyl-α-D-glucoside (0.3 ml) was added and then incubated at 37° C. for 30 min.
  • After that, the reaction was suspended by adding 3 ml glycin buffer solution (pH10.3) and the quantity of the isolated 4-methylumbelliferyl was determined by using a fluorometer (excitation wavelength: 366 nm & fluorescent wavelength: 450 mm). Enzyme activity was calculated based on this determined value and inhibitory activity (%) was calculated by the following formula. Also, the enzyme activity was calculated based on the determined value (100%) of 4-methylumbelliferyl measured under condition where no sample coexisted.
    Inhibitory activity (%)=100−Enzyme activity (%)
  • As a comparison, the inhibitory activities (%) in regard to the plant-derived extracts—guava leaf extract (Comparison 1), banaba leaf extract (Comparison 2), and mulberry leaf (Comparison 3) were identified by the same method. Result is shown in the following chart 2.
    CHART 2
    Concentration Inhibitory
    Classification Extract (mg/ml) activity (%)
    Embodiment 1 Evening 0.1 65
    primrose seed
    Comparison 1 Guava leaf 0.1 77
    Comparison 2 Banaba leaf 0.1 76
    Comparison 3 Mulberry leaf 0.1 96
  • As indicated in Chart 2, although inhibitory activity against α-glucosidase of embodiment 1 (evening primrose seed extract) is less effective than that of guava leaf extract (Comparison 1), banaba leaf extract (Comparison 2) and mulberry leaf extract (Comparison 3), it still has excellent inhibitory activity against α-glucosidase.
  • After measuring the enzyme activities to the variation of concentration in regard to the embodiment 1 (evening primrose seed extract), gallic acid, ellagic acid, catechin and penthagalloylglucose by using the same method, IC50 (50% inhibitory concentration) against α-glucosidase was identified.
  • The following chart shows the excellent inhibitory activities.
    Chemical compound IC50 (mg/ml)
    Embodiment 1 (evening primrose seed extract) 0.1
    Gallic acid 0.8
    Ellagic acid >0.08
    Catechin 0.8
    Pentagalloylglucose 0.04
  • Those test results indicate that the embodiment 1 (evening primrose seed extract) comprises the inhibitory activity against both α-amylase and α-glucosidase, and effectively inhibits the degradation of carbohydrate.
  • (Carbohydrate Loading Test to Normal Rats)
  • In regard to the embodiment 1 (evening primrose seed extract), carbohydrate absorption inhibitory action in living animals was tested under the following conditions.
  • After breeding 5-week old male wister rats (Clear Japan, Inc.) for more than one week, then 6 to 8-week old wister rats were used during the test. Without giving any food to the rats for 24 hours, sample of Embodiment 1 (at the rate of 0.5 g per kg of weight) was dissolved in distilled water, and carbohydrate (starch and sucrose: at the rate of 2 g per kg of weight) was dissolved in distilled water, then both were administered to the stomach sound.
  • To measure a variation of the blood glucose level after administering the samples to the rats, blood was taken from the vain of tails before the samples were administered, and at each stage of 30, 60, 120 and 180 min after the samples were administered. As a control group, blood was taken from the vain of the tails of the rats under the same conditions where the sample, the same amount of distilled water and carbohydrate (starch and sucrose at the rate of 2 g per kg of weight) were administered to the rats.
  • After centrifuging the blood taken from the rats, the blood glucose level of the supernatant was measured. For measuring the blood glucose level, a glucose measuring kit commercially available was used. (“Glucose B Test Wako” manufactured by Wako Pure Chemical Industries, Ltd., Japan) The results are shown in FIG. 1 and FIG. 2.
  • As shown in FIG. 1 and FIG. 2, in a control group, the blood glucose level rapidly increased before 30 min passed, on the contrary, the blood glucose level of the rats of which the embodiment 1 (evening primrose seed extract) was administered slowly increased.
  • (Application to Food and Drink)
  • Application to food and drink which are effective for the prevention of diabetes mellitus and diet are as follows. “Evening primrose seed extract” shown below is powdered and dried ethanol extract of evening primrose seed obtained under the same conditions of the aforementioned embodiment 1.
    Composition 1: Chewing gums
    Sugar 53.0 wt %
    Gum base 20.0
    Glucose 10.0
    Starch syrup 16.0
    Flavoring agent 0.5
    Evening primrose seed extract 0.5
    100.0 wt %
    Composition 2: Gummy candies
    Reduced syrup 40.0 wt %
    Granulated sugar 20.0
    Glucose 20.0
    Gelatin 4.7
    Water 9.68
    Japanese apricot (Ume) juice 4.0
    Japanese apricot (Ume) flavor 0.6
    Coloring agent 0.02
    Evening nrimrose seed extract 1.0
    100.0 wt %
    Composition 3: Candies
    Sugar 50.0 wt %
    Starch syrup 33.0
    Water 14.4
    Organic acid 2.0
    Flavoring agent 0.2
    Evening primrose seed extract 0.4
    100.0 wt %
    Composition 4: Soft capsule
    Rice germ oil 87.0 wt %
    Emulsifying agent 12.0
    Evening primrose seed extract 1.0
    100.0 wt %
    Composition 5: Soft drink
    Fructose and glucose 30.0 wt %
    Emulsifying agent 0.5
    Evening primrose seed extract 0.05
    Flavoring agent Minute
    amount
    Distilled water Rest
    100.0 wt %
    Composition 6: Tablets
    Lactose 54.0 wt %
    Crystallized cellulose 30.0
    Starch degradation product 10.0
    Glycerin fatty acid ester 5.0
    Evening primrose seed extract 1.0
    100.0 wt %
    Composition 7: Tablet-shaped candies
    Sugar 76.4 wt %
    Glucose 19.0
    Glycerin fatty acid ester 0.2
    Evening primrose seed extract 0.6
    Distilled water 3.9
    100.0 wt %
  • The structure of the extract obtained from the embodiment 1 and similar method contained ellagic acid, gallic acid, catechin, and pentagalloylglucose.
  • (Beginning of the Additional Part)
  • Analysis in regard to evening primrose seed extract in this invention is shown in chart 3 below.
    CHART 3
    Sample Gallic acid Catechin Ellagic acid PGG*1
    Evening 2.7% 1.6% 0.5% 2.3%
    primrose
    extract Lot:
    R-006

    *1Pentagalloylglucose
  • Also, HPLC chart is shown in FIG. 3. Considering the above result, it is recognized that the extract obtained in this invention contains gallic acid, catechin, ellagic acid and pentagalloylglucose. It is still impossible to create a sample excluding the specific component from the evening primrose seed extract even by the present technology. Therefore, performance test should be still conducted by using a mixture of various components. After measuring the effectiveness to inhibit the after-meal elevated blood glucose level of 16 normal persons female:male=7:9), the result in FIG. 4 shows that blood glucose level of subjects in 30 minutes after taking evening primrose is controlled. Also, the rise in blood glucose level of the patient suffering from the mild diabetes mellitus with the fasting blood glucose level of 110 mg/dl to 180 mg/dl is more significantly controlled than the rise in postprandial blood glucose level of the patient in a placebo group.
    CHART 4
    Change in the value of insulin when conducting the food loading test (μU/dl)
    Before
    loading test 30 min 60 min 90 min 120 min
    Control 13.3 ± 15.0 28.4 ± 23.9 40.0 ± 31.1 43.6 ± 28.1 50.1 ± 30.0
    group
    Evening primrose 12.7 ± 9.8  22.4 ± 14.5 35.8 ± 33.1 43.7 ± 35.9 43.7 ± 31.4
    extract group
    Significant n.s n.s n.s n.s n.s
    difference
    between
    groups
  • It is apparent that evening primrose comprises an effective function to control the rapid rise in blood glucose-level after food loading. Since the rapid rise in blood glucose level is controlled, the rapid increase in insulin secretion becomes moderate. This indicates that evening primrose extract is effective to reduce the burden of insulin secretion of the patient suffering from insulin deficiency diabetes mellitus.
  • (End of the Additional Part)
    • INDUSTRIAL APPLICABILITY
  • (Beginning of the Additional Part)
  • The amount of carbohydrate taken into the human body can be controlled by inhibiting the digestion of starch and saccharides, i.e., by inhibiting the activity of a amylase and α-glucosidase which are saccharides degrading enzyme inherent in living body. The risk of type II diabetes mellitus can be especially controlled by a mechanism which keeps the postprandial blood glucose level low.
  • The said mechanism is significantly safer and harmless than the direct prevention to control the insulin secretion, and from the viewpoint of the preventive medicine in the latest mainstream of alternative medicine, it is considered to be inventive that the said mechanism can be applied to the function of the evening primrose leaf extract.
  • Also clinical investigation of the diabetes patient apparently shows that administration of evening primrose does not directly enhance the insulin secretion, and decrease in the blood glucose level of human and animals apparently indicates that evening primrose extract inhibit the absorption of the saccharides.
  • (End of the Additional Part)
  • As described above, absorption of saccharides can be effectively controlled in this invention.
  • Also this invention can provide the significant effectiveness to prevent and treat diabetes mellitus and obesity since the rise in blood glucose level by absorption of saccharides becomes moderate.
  • Furthermore, in this invention, effective component is extracted from evening primrose seed which is known as an ingredient of edible oil, therefore the said component is safe and has no side effect or the like.

Claims (13)

1-6. (canceled)
7. In a method of administering treatment to a patient suffering from diabetes mellitus, the improvement comprising administering to the patient an effective amount of an carbohydrate absorption inhibitor comprising an effective component of solvent extract of compressed cake derived from defatted evening primrose seed and wherein the effective component contains polyphenol—essential elements comprising ellagic acid, gallic acid, pentagalloylglucose and catechin.
8. In a method of administering treatment to patients suffering from obesity, the improvement comprising administering to the patients an effective amount of the carbohydrate absorption inhibitor comprising an effective component of solvent extract of compressed cake derived from defatted evening primrose seed and wherein the effective component contains polyphenol—essential elements comprising ellagic acid, gallic acid, pentagalloylglucose and catechin.
9. The method of claim 7, wherein an extracting solvent of the compressed cake derived from the evening primrose seed is 55 to 99% (v/v) aqueous ethanol.
10. The method of claim 8, wherein an extracting solvent of the compressed cake derived from the evening primrose seed is 55 to 99% (v/v) aqueous ethanol.
11. The method of claim 9, wherein an extracting solvent of the compressed cake derived from the evening primrose seed is 70 to 85% (v/v) aqueous ethanol.
12. The method of claim 10, wherein an extracting solvent of the compressed cake derived from the evening primrose seed is 70 to 85% (v/v) aqueous ethanol.
13. The method of claim 7, wherein a fat-soluble organic solvent is used in when defatting the evening primrose seed.
14. The method of claim 8, wherein a fat-soluble organic solvent is used in when defatting the evening primrose seed.
15. The method of claim 7, wherein patients receive the effective amount of the carbohydrate either orally or by injection.
16. The method of claim 8, wherein patients receive the effective amount of the carbohydrate either orally or by injection.
17. The method of claim 7, wherein oil is removed from the evening primrose seed by first compressing the seed into a cake for oil removal, and then using a solvent to remove remaining oil from the cake.
18. The method of claim 8, wherein oil is removed from the evening primrose seed by first compressing the seed into a cake for oil removal, and then using a solvent to remove remaining oil from the cake.
US10/803,873 2000-08-01 2004-03-19 Method of treating diabetes and obesity using carbohydrate absorption inhibitors Abandoned US20060024396A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/803,873 US20060024396A1 (en) 2000-08-01 2004-03-19 Method of treating diabetes and obesity using carbohydrate absorption inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000-232930 2000-08-01
JP2000232930 2000-08-01
US10/343,488 US6932990B2 (en) 2000-08-01 2001-07-26 Carbohydrate absorption inhibitor and method for manufacturing the same
PCT/JP2001/006436 WO2002009734A1 (en) 2000-08-01 2001-07-26 Sugar absorption inhibitors and process for producing the same
US10/803,873 US20060024396A1 (en) 2000-08-01 2004-03-19 Method of treating diabetes and obesity using carbohydrate absorption inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2001/006436 Division WO2002009734A1 (en) 2000-08-01 2001-07-26 Sugar absorption inhibitors and process for producing the same
US10/343,488 Division US6932990B2 (en) 2000-08-01 2001-07-26 Carbohydrate absorption inhibitor and method for manufacturing the same

Publications (1)

Publication Number Publication Date
US20060024396A1 true US20060024396A1 (en) 2006-02-02

Family

ID=18725531

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/343,488 Expired - Fee Related US6932990B2 (en) 2000-08-01 2001-07-26 Carbohydrate absorption inhibitor and method for manufacturing the same
US10/803,873 Abandoned US20060024396A1 (en) 2000-08-01 2004-03-19 Method of treating diabetes and obesity using carbohydrate absorption inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/343,488 Expired - Fee Related US6932990B2 (en) 2000-08-01 2001-07-26 Carbohydrate absorption inhibitor and method for manufacturing the same

Country Status (8)

Country Link
US (2) US6932990B2 (en)
EP (1) EP1312374B1 (en)
JP (1) JP4873824B2 (en)
CN (1) CN1268351C (en)
AT (1) ATE407689T1 (en)
AU (1) AU2001276682A1 (en)
DE (1) DE60135760D1 (en)
WO (1) WO2002009734A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244096A1 (en) * 2009-09-16 2012-09-27 Chen Xie Plant extract, compositions containing same, method of extraction and uses thereof
EP3431094A1 (en) * 2008-08-22 2019-01-23 Vifor Pharma Innovation Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
KR20030075947A (en) * 2002-03-19 2003-09-26 제네티카 주식회사 Angiogenesis inhibitor
EP1545554A4 (en) * 2002-07-24 2006-06-14 Univ Ohio METHODS AND COMPOSITIONS FOR TREATING SUGAR DIABETES
JP4541662B2 (en) * 2003-05-29 2010-09-08 オリザ油化株式会社 Anti-pylori composition
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
JP2006335758A (en) * 2003-10-06 2006-12-14 Oriza Yuka Kk Composition for diet
JP4499665B2 (en) * 2003-10-06 2010-07-07 オリザ油化株式会社 Diet composition
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP1557094A1 (en) * 2004-01-26 2005-07-27 Wageningen Centre for Food Sciences Improved semi-solid food products and methods for their production based on inhibiting amylase induced starch breakdown
US20050251265A1 (en) * 2004-05-07 2005-11-10 Calandruccio James H Trapezium implant for thumb and method
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
US20050249837A1 (en) * 2004-05-10 2005-11-10 The Procter & Gamble Company Processes for preparing plant matter extracts and pet food compositions
BRPI0511227A (en) 2004-06-04 2007-11-27 Horizon Science Pty Ltd molasses extract, sugar sludge extract, broth and / or foam extract collected from the clarification tank, extract of fibrous / residual sugarcane stalks from the sugar beet or sugarcane field, bagasse extract and extract of sugar beet pulp having characteristics reducing ig or burning rate; method for the extraction of non-nutrient phytochemicals which have reducing properties of ig or the rate of burning of sugar processing waste stream and other products in process and sugarcane milling sludge; method for decreasing the ig of a food product; sucrose product containing low ig; method for obtaining food products having a lower ig or lower burn rate; method to improve health; method for decreasing the ig of a sucrose-containing product; low ig product; purified phytochemical extracted from sugar cane or sugar beet; low ig sweetener and sweetener
JP5020462B2 (en) * 2004-06-16 2012-09-05 クラシエフーズ株式会社 α-Glucosidase inhibitor and food using the same
JP2006016330A (en) * 2004-06-30 2006-01-19 Suntory Ltd Fat-burning accelerating agent
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
JP2006056850A (en) * 2004-08-23 2006-03-02 Suntory Ltd Lipase inhibitor
WO2006025551A1 (en) 2004-08-30 2006-03-09 Takeda Pharmaceutical Company Limited Screening method
JP2006104181A (en) * 2004-09-13 2006-04-20 Takahiro Tsujita Glucide-splitting enzyme-inhibiting material derived from fagaceae plant and application thereof
CN100566723C (en) * 2004-09-13 2009-12-09 辻田隆广 Carbohydrase inhibitors derived from Faga plants and their applications
EP1880001B1 (en) 2005-05-31 2011-06-08 The Iams Company Feline probiotic lactobacilli
PL1885383T3 (en) 2005-05-31 2017-06-30 Iams Europe B.V. Feline probiotic bifidobacteria
AU2006254652B2 (en) * 2005-06-03 2011-04-21 Poly Gain Pte Ltd Substances having body mass redistribution properties
WO2007019526A2 (en) * 2005-08-05 2007-02-15 Naturegen, Inc. Compositions and methods for controlling glucose and lipid uptake from foods
KR100829083B1 (en) 2006-07-28 2008-05-16 재단법인 제주하이테크산업진흥원 Baby Evening Primrose Extract with Biological Activity
CA2662364C (en) * 2006-09-19 2016-10-18 Horizon Science Pty Ltd Extracts derived from sugar cane and a process for their manufacture
BRPI0808391A2 (en) * 2007-02-01 2014-07-08 Lams Company METHOD FOR REDUCING INFLAMMATION AND STRESS IN A MAMMALIAN BY USING GLUCOSE ANTITABOLITES, AVOCADO OR AVOCRATE EXTRACTS.
RU2429853C2 (en) * 2007-02-01 2011-09-27 Дзе Иамс Компани Method to reduce inflammation and oxidation stress in mammals
WO2009137859A1 (en) 2008-05-15 2009-11-19 Alois Jungbauer Compounds for the treatment of metabolic syndrome and insulin resistance
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN102170890B (en) * 2008-10-08 2013-03-20 百佳株式会社 Anti-avian influenza virus agent, and product containing anti-avian influenza virus agent
JP2010184909A (en) * 2009-02-13 2010-08-26 Rheology Kino Shokuhin Kenkyusho:Kk Functional composition and pharmaceutical or health food comprising the composition
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
AU2012214104C1 (en) 2011-02-08 2017-08-03 Poly Gain Pte Ltd Sugar extracts
RU2451506C1 (en) * 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Combination for treatment of diabetes and complications thereof
SG11201501044RA (en) 2012-08-28 2015-05-28 Product Makers Australia Pty Ltd Extraction method
JP2014198684A (en) * 2013-03-29 2014-10-23 サンスター株式会社 Blood sugar metabolism improver
WO2015021512A1 (en) 2013-08-16 2015-02-19 Horizon Science Pty Ltd Sugar cane derived extracts and methods of treatment
JP6998108B2 (en) 2016-03-07 2022-01-18 株式会社ダイセル Α-Glucosidase activity inhibitor containing urolithins and blood glucose increase inhibitor containing urolithins
US20200315998A1 (en) * 2017-12-27 2020-10-08 Suntory Holdings Limited Composition for improving intestinal barrier function
JPWO2022085602A1 (en) * 2020-10-20 2022-04-28

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018013B2 (en) * 1989-10-19 2000-03-13 三井農林株式会社 α-amylase activity inhibitor
JPH09176019A (en) * 1995-12-26 1997-07-08 Suntory Ltd Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith
PT815857E (en) * 1995-12-26 2005-01-31 Suntory Ltd ANTI-OBESITY AGENT PROCIANIDIN AS ACTIVE INGREDIENT
WO2000018416A1 (en) * 1998-09-30 2000-04-06 Industrial Research Limited Antioxidant compositions and process for their preparation

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431094A1 (en) * 2008-08-22 2019-01-23 Vifor Pharma Innovation Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
EP4201408A1 (en) * 2008-08-22 2023-06-28 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US20120244096A1 (en) * 2009-09-16 2012-09-27 Chen Xie Plant extract, compositions containing same, method of extraction and uses thereof
US8980343B2 (en) * 2009-09-16 2015-03-17 Botanic Century Beijing Co. Ltd. Plant extract, compositions containing same, method of extraction and uses thereof
US10016474B2 (en) 2009-09-16 2018-07-10 Botanic Century Beijing Co. Ltd. Plant extract, compositions containing same, method of extraction and uses thereof
US11090349B2 (en) 2009-09-16 2021-08-17 Botanic Century Beijing Co. Ltd Plant extract obtained from Morus plant leaves, compositions containing same, method of extraction and uses thereof
US11865155B2 (en) 2009-09-16 2024-01-09 Botanic Century (Beijing) Co. Ltd. Plant extract obtained from Morus plant leaves which has an IC50 value to inhibit a-glucosidase I at a concentration of less than 90 uG/ml, compositions containing same, method of extraction and uses thereof

Also Published As

Publication number Publication date
US6932990B2 (en) 2005-08-23
CN1268351C (en) 2006-08-09
AU2001276682A1 (en) 2002-02-13
WO2002009734A8 (en) 2002-02-28
DE60135760D1 (en) 2008-10-23
CN1468106A (en) 2004-01-14
JP4873824B2 (en) 2012-02-08
WO2002009734A1 (en) 2002-02-07
US20030161903A1 (en) 2003-08-28
EP1312374A1 (en) 2003-05-21
EP1312374A4 (en) 2004-04-21
ATE407689T1 (en) 2008-09-15
EP1312374B1 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
US6932990B2 (en) Carbohydrate absorption inhibitor and method for manufacturing the same
EP0815857B1 (en) Antiobestic agent containing procyanidin as the active ingredient
JPH09291039A (en) Antiobestic medicine comprising procyanidin as active ingredient
US20060188590A1 (en) Compositions for treating diabetes or obesity
JPH09176019A (en) Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith
KR20140090453A (en) Composition comprising aronia extract for preventing and relieving hangover, and for protecting the alcohol-damaged hepatocyte
US20190076496A1 (en) Polysaccharide digestion inhibitor
EP2052729B1 (en) Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia
KR101616811B1 (en) Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa
US10646527B2 (en) Method of using a Mangifera indica composition in the treatment of obesity
KR20150136668A (en) Composition for antidiabetic or antiobesity activity comprising sprout extract as effective component
JP2007520548A (en) Composition for prevention and treatment of diabetic complications
CN101646428A (en) Be used for the treatment of or prevent diabetes comprise medical composition and its use from the alkannin derivant of Radix Arnebiae (Radix Lithospermi)
KR20180137971A (en) Composition of the hot water extract of Dendropanax morbiferus Lev. having anti-apoptotic activity for preventing and treating of neurodegenerative diseases
KR20190066460A (en) Pharmaceutical composition comprising the seed extracts of rambutan as an effective component for prevention or treatment of diabetes and health functional food comprising the same
JP2004091462A (en) Carbohydrate absorption inhibitor
US20180110792A1 (en) Compositions and methods for inhibiting glycation reactions
JP2003095941A (en) Carbohydrate digestive enzyme inhibitor, blood sugar rise inhibitor, obesity treatment / prevention agent, diabetes treatment / prevention agent, healthy food and drink
JP2002053476A (en) Hyperlipidemia preventive and ameliorating agent and food and beverage containing it
JPWO2005082390A1 (en) Fat accumulation inhibitor
KR100560411B1 (en) Hangover cure containing green tea catechin as an active ingredient
EP3235510A1 (en) Nutritional compositions for the management of glucose metabolism
EP2052728B1 (en) Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
EP3009138A2 (en) Herbal composition for the management of obesity and/or weight
JP2006083106A (en) Drugs and foods and drinks that have an inhibitory effect on blood neutral fat concentration

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载